NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says

MT newswire2026/10/05 15:34

11:34 AM EDT, 10/05/2026 (MT Newswires) -- NewAmsterdam Pharma's (NAMS) PREVAIL phase 3 trial faces "considerable" risk at the interim analysis, but could prevail eventually, RBC said in a report Monday after an "in-depth" statistical analysis. The report said proprietary work finds risk on potentially too few MACE-3 events, with 35% to 38% probability of success for the interim results. "Still, we see a number of potential mitigators, including that our assumptions may be more conservative than necessary, a high PoS final analysis by end-'27, and investor sentiment which we think may be reflecting a miss already," the report said. The PREVAIL interim announcement in Q1 of 2027 is expected to be the largest near-term catalyst, the note said. RBC cut its price target to $42 from $50 to reflect caution on the interim analysis and the more negative investor sentiment. "We still think risk/reward at these levels could skew favorably, and remain outperform," the report said. Price: 22.64, Change: -0.56, Percent Change: -2.41

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned

According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.

智通财经•2026/11/09 11:09

Eurozone Sentix Investor Confidence Index slips to 2.4 in November from 2.7 in October

FXStreet•2026/11/09 10:57

The UK Financial Conduct Authority allows banks to submit applications for crypto-related businesses.

AiCoin•2026/11/09 10:45

SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries

A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.

华尔街见闻•2026/11/09 10:26